Safety Study of Sargramostim in Treating Patients With Mild Cognitive Impairment Due to Alzheimer's Disease

Summary

Primary Objective: To compare the effect of repeat doses of Leukine to placebo administered subcutaneously (SC) on established cortical amyloid load in patients with mild cognitive impairment (MCI) due to Alzheimer's disease (AD). Secondary Objective: * To evaluate safety and tolerability of Leukine versus placebo. * To explore the effect of Leukine versus placebo on cognitive performance. * To collect biospecimens for future biomarker research.

Timeline

Start

2016-11

Primary completion

2017-03-31

Completion

2017-03-31

Outcome

Outcome not reported

Stopped (Enrollment): “Slow recruitment”

Drugs

Indications